Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human safety study of IMP761 in healthy volunteers
NL-OMON60253Phase 1Completed
- Sponsor
- Immutep Limited
- Start
- Jul 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1 trial of IMP761 in autoimmune disease, sponsored by Immutep Limited. Started Jul 2024; status: completed.
02
Drugs
IMP761
03
Conditions
autoimmune disease
Beyond the preview
Go deeper on NL-OMON60253.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60253.